South America Self-Blood Glucose Monitoring Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Self-Blood Glucose Monitoring Market Trends and Insights

Rising Diabetes Prevalence and Undiagnosed Burden

The South America self-blood glucose monitoring market is supported by the large number of adults who live with diabetes without a diagnosis. The IDF recorded 35.4 million adults with diabetes in South and Central America in 2024. It also reported that 10.7 million adults were undiagnosed, representing 30.4% of adults with diabetes. These individuals may require entry-level meters and supplies when screening identifies their condition. Brazil had 17 million people with diabetes in 2024, which made it the region’s largest source of patient demand. Screening activity converts a previously unmonitored population into people who need regular testing, although out-of-pocket costs can limit testing frequency.

Public Provision and Reimbursement of SMBG Supplies

Public reimbursement gives the South America self-blood glucose monitoring market a predictable institutional sales channel. Brazil’s public health system has provided glucometers and test strips without charge to insulin-dependent patients under Portaria nº 2.583 since 2007^{[1]Brazilian Ministry of Health, “Portaria nº 2.583: Dispensação de Medicamentos e Insumos para o Tratamento do Diabetes Mellitus no SUS,” Brazilian Ministry of Health, diretriz.diabetes.org.br}. Product specifications in these tenders influence which suppliers can compete for public contracts. Argentine obras sociales and PAMI also support access to self-monitoring supplies, although currency depreciation raises procurement costs. Brazil’s national health technology assessment process did not add flash CGM to the public system in its January 2025 recommendation, leaving conventional monitoring supplies relevant for covered patients. Tender access can give suppliers multiyear volume visibility that is not available through retail sales alone.

Shift to Home-Based Diabetes Self-Management and Digital Enablement

Home-based management remains important to the South America self-blood glucose monitoring market because many patients test outside formal care settings. A Brazilian real-world study found that 86.5% of tracked users used blood glucose meters rather than flash CGM. The same study found lower mean 24-hour glucose among flash CGM users than blood glucose meter users, although the difference was not statistically significant. This supports the continued clinical role of blood glucose meters for patients who cannot afford a CGM. Bluetooth-enabled meters and companion applications can turn individual tests into stored records. These records may help patients follow their testing routines and allow clinicians to review without a routine office visit.

Expansion of Retail and E-Pharmacy Fulfillment

Retail and online distribution extend the South America self-blood glucose monitoring market beyond public procurement routes. Pharmacies can reach people in secondary cities where public supply is less consistent. Retail outlets provide immediate access to meters, lancets, and replacement strips. Online pharmacies support recurring delivery of supplies for people who already use a compatible meter. Subscription delivery can reduce the effort of replacing strips and help patients maintain their testing routine. The growth of online purchasing, therefore, complements, rather than replaces, the retail pharmacy base.

Accelerating CGM Adoption Among Insulin Users: Reducing Fingerstick Frequency

CGM adoption can reduce demand for frequent fingerstick testing among insulin-dependent patients in the South America self-blood glucose monitoring market. These patients often consume the highest volumes of test strips because they test more often. Chile expanded CGM coverage in December 2025 for people under 18 and pregnant women with Type 1 diabetes. Brazil is evaluating real-time CGM coverage for Type 1 diabetes through Consulta Pública 63/2026. The Brazilian real-world study found that 87.6% of flash CGM users had Type 1 diabetes. Brazil’s January 2025 decision on flash CGM indicates that the transition in the public system remains gradual.

Import Dependence, Foreign-Exchange Volatility, and Price Caps

Imported devices and supplies expose the South America self-blood glucose monitoring market to currency movements and procurement limits. Argentina faces the most serious exposure because peso depreciation raises the local cost of imported meters and strips. Public purchasing rules can limit the prices that buyers pay, which can narrow supplier margins. Ascensia Diabetes Care discontinued the Contour Plus product range in Brazil from August 2024. Customs duties can add 10% to 25% to landed costs, depending on trade agreement status. Local manufacturing capacity and currency hedging can therefore be important for suppliers that need stable pricing.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Component: Test Strip Dominance Reinforces Recurring Revenue Dynamics

Test strips held 82.31% of the South America self-blood glucose monitoring market share in 2025 and recorded a 5.58% CAGR through 2031. Their leading position reflects the repeated use of strips after a meter is placed. Each test requires a compatible consumable, which creates a continuing purchase cycle. Meters can be subsidized or included in reimbursement programs to encourage access. That approach can increase the installed base for a supplier’s proprietary strip format. The recurring nature of strips makes a stable supply a priority for pharmacies, public buyers, and patients.

Lancets are usually bundled with other products at the point of sale. They are less likely to make a purchase decision on their own. Their quality can still affect testing regularity, especially for pediatric users, where lower pain can support use. The IDF recorded 967,187 live births affected by hyperglycemia in pregnancy in South and Central America during 2024. These pregnancies create a defined period when intensive monitoring may be needed. This demand supports the use of strips among patients managing gestational diabetes.

By Diabetes Type: Type 2 Anchors Volume, Gestational Sets the Growth Pace

Type 2 diabetes held 89.24% revenue share in 2025. Its large share aligns with the broad prevalence of Type 2 diabetes across income groups in the region. Many people with Type 2 diabetes require periodic glucose checks rather than continuous monitoring. This care pattern supports sales through retail pharmacies and hospital procurement. The high patient base gives suppliers a broad volume foundation. It also leaves affordability and refill access central to regular testing.

Gestational diabetes is forecast to grow at a 7.22% CAGR through 2031. A 2024 Buenos Aires hospital study recorded gestational diabetes in 9% of pregnancies^{[2]Salud Pública, “Estudio sobre la Prevalencia de Diabetes Gestacional en el Hospital Interzonal Dr. Alberto Eurnekian de Ezeiza,” Ministerio de Salud de Buenos Aires, saludpublica.ms.gba.gov.ar}. A provincial maternity center reported an incidence rising from 16.8% in 2021 to 37.1% in 2023 after it adopted more sensitive diagnostic protocols. Wider screening in Brazil and Colombia is expected to identify more patients during pregnancy. These patients need intensive monitoring for a limited care period.

By Distribution Channel: Online Pharmacies Disrupting a Retail-Dominant Base

Retail pharmacies accounted for 46.14% revenue share in 2025. They remain the most established distribution route for people purchasing meters and strips directly. Pharmacies offer product access, refill convenience, and local advice. They also provide a familiar option for people who do not use online purchasing. This channel remains important even as digital ordering becomes more common. Its broad physical presence supports access in cities and smaller population centers.

Online pharmacies are projected to expand at a 7.82% CAGR through 2031. Their growth is linked to e-pharmacy use, chronic-disease subscriptions, and digital health purchasing behavior. Online ordering can simplify repeat purchases of compatible strips. B2B sales through hospitals, institutional tenders, and distributors remain an important volume tier. These contracts often run for multiple years and use fixed specifications. Brazil’s online pharmacy revenue was reported as significant in 2025, although no specific value was provided in the source material.

By End User: Homecare at the Core of Regional SMBG Growth

Homecare held 58.65% revenue share in 2025 and is forecast to grow at a 5.65% CAGR through 2031. The segment reflects the large number of people who manage diabetes outside hospitals and clinics. Brazil’s SUS policy provides meters and strips to eligible insulin-dependent patients for home monitoring. Home testing can reduce the need for a clinical visit for routine measurement. It also aligns with connected meters that allow data to be stored and reviewed remotely.

Hospitals and clinics retain demand for point-of-care testing in inpatient wards and emergency settings. These settings need timely results and calibrated accuracy. Diagnostic centers serve a smaller group of patients undergoing structured diabetes assessments. They are less focused on routine self-monitoring than homecare settings. Their role can become smaller as home-use monitoring is included more fully in care pathways. The South America self-blood glucose monitoring industry, therefore, depends on both home use and institution-based testing needs.

Geography Analysis

Brazil held 52.61% revenue share in 2025 and is forecast to grow at a 6.25% CAGR through 2031. SUS procurement creates an institutional demand base for eligible insulin-dependent patients. Suppliers need ANVISA registration and tender-compliant products to compete for government supply contracts. These contracts can provide volume visibility over multiple years. Brazil also has private demand through pharmacies and digital channels.

ANVISA’s RDC 830/2023 entered into force on June 1, 2024. The resolution modernized risk-based registration for in vitro diagnostic devices and aligned requirements with EU and IMDRF standards. The rules raise compliance requirements for importers. The Brazilian Glic platform reported that Southeast Brazil represented 57% of its user base. This concentration reflects activity in São Paulo and Rio de Janeiro, where private health coverage and digital health use are stronger.

Argentina held the second-largest country share in 2025. PAMI provides self-monitoring supplies as a formal benefit, creating demand among pensioners. Currency instability affects the cost of imported products and public purchasing. Colombia, Chile, and Peru represent a middle group with different demand conditions. Chile’s GES program covers diabetes monitoring supplies and expanded CGM access in December 2025 for minors and pregnant people with Type 1 diabetes. A Lima screening study estimated gestational diabetes prevalence at 16%, which points to demand not fully served through existing channels. Bolivia, Ecuador, Paraguay, and Uruguay rely more on retail and informal channels, with demand growing as screening reaches lower-income urban populations.